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Background: There is little information regarding the composition of peripheral blood immunity in sarcoma
patients and even less in the context of pediatric sarcomas. We describe the immune status using flow cytometry
of peripheral blood in patients with osteosarcoma and Ewing sarcoma and demonstrate excessive CD14 in tumor
tissues.
Methods: Peripheral blood from patients with OS and ES was collected at diagnosis or relapse, and used for
immune phenotyping of 74 different leukocyte phenotypes. Blood from young adult healthy volunteers was
collected as controls. Tumor tissues were analyzed by immunohistochemistry.
Results: Nineteen patients (average age = 14 y) and 16 controls (average age = 25y) were enrolled on study. Of the
74 phenotypes, 14 were different between sarcoma patients and HV. Sarcoma patients’ leukocytes contained a
higher percentage of granulocytes (67 % sarcoma vs. 58 % HV; p = 0.003) and fewer lymphocytes (20 % sarcoma vs.
27 % HV; p = 0.001). Increased expression of CTLA-4 was seen in both T cells in sarcoma patients as compared to
HV (p = 0.05). Increased CD14+ HLA-DRlo/neg immunosuppressive monocytes were seen in sarcoma patients
(p = 0.03); primarily seen in OS. Increased tumor necrosis factor receptor II expression was seen on CD14+ cells
derived from sarcoma patients as compared to HV (p = 0.01). Massive infiltration of CD14+ cells was seen in OS
(>50 % of cells in the majority of tumors) compared to ES (<10-25 % of cells). In contrast, both OS and ES had
limited T cell infiltration (generally <10 % of cells).
Conclusions: Pediatric sarcoma patients exhibit several immune phenotypic differences that were exacerbated in
more severe disease. These phenotypes have the potential to contribute to immune suppression and may indicate
potential targets for immune therapies.
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Pediatric bone sarcomas are rare tumors with overall inci-
dence of 700 cases of osteosarcoma (OS) and 200 cases of
Ewing sarcoma (ES) annually in the United States [1, 2].
Overall prognosis of advanced and relapsed pediatric sar-
comas is dismal with 5-year event free survival less than
20 %. Treatment options for such patients have included
chemotherapy, surgery and radiation therapy at the sites
of recurrence although none of these approaches are gen-
erally curative. New approaches to therapy are needed to
improve overall survival in this group of patients.
Immune dysregulation is an important contributing
mechanism to the development of a variety of human
cancers. Indeed, patients with common variable im-
munodeficiency are known to be at increased risk of de-
veloping lymphomas [3]. For example, EBV-associated
solid tumors have been seen with increased frequency in
patients with immune dysregulation such as after trans-
plantation or in the setting of HIV/AIDS [4]. Immune
system abnormalities have also been reported in solid tu-
mors. Loss of CD27+ memory B cells, poor chemokine
mediated trafficking of effector cells and inhibition of T-
cell function by negative regulatory pathways have been
noted in melanomas [5, 6]. Similarly, stage III and IV
head and neck cancer patients have been shown to have
down regulated NK cell and NK-T cell populations and
up regulation of suppressor regulatory T cells (Tregs)
[7]. These mechanisms together and alone are thought
to represent the mechanism of tumor cell evasion from
host’s immune surveillance.
Several reports exist of various immune abnormalities
in patients with sarcomas including reduced Class I and
Class II human leukocyte antigen (HLA) cell surface ex-
pression especially in metastatic and progressive tumors
[8] and increased proportion of Tregs seen in bone mar-
row of patients with metastatic ES [9]. To date, analysis
of most tumor immunity and particularly sarcomas have
focused on single phenotypes, with extrapolation that
these single phenotypes are representative of the im-
mune system.
The lack of therapeutic options in sarcomas has led to
interest in immune based therapies. For example, studies
have used dendritic cells pulsed with tumor lysates or
tumor specific antigens to stimulate anti-tumor immun-
ity in ES and rhabdomyosarcoma [10–14]. Although
safe, the success rate of therapy with dendritic cell vac-
cines in pediatric solid tumor patients has been modest.
Improved responses for this and other immunotherapy
approaches could benefit from a more complete under-
standing of the immune status of patients. In this study
we have taken a broad approach to understanding im-
mune dysfunction by assessing over 70 distinct immune
phenotypes by flow cytometry. The compilation of phe-
notypes was used to generate an immune profile foreach individual. The immune profiles of OS and ES pa-
tients and compared it to non-cancerous healthy volun-
teers in an effort to define the extent of immune
dysfunction in pediatric sarcoma patients.
Methods
Patients
Institutional review board approval was obtained from
Phoenix Children’s Hospital and the Mayo Clinic prior
to the commencement of the study. Patients with newly
diagnosed or relapsed OS and ES at Phoenix Children’s
Hospital (PCH) were enrolled in this study after in-
formed consent. HV between the ages of 18–30 years
were provided with a screening questionnaire to exclude
any underlying acute or chronic infections/ immunologic
disorders as well as prior history of cancer. Up to 45 ml
of blood in sodium heparin and 5 ml of blood in ethyl-
enediamine tetraacetate (EDTA) was collected from pa-
tients and 10 ml of blood was collected from HV.
Patients were required to have been off any myelosup-
pressive chemotherapy for four weeks prior to the time
of sample collection. Blood was shipped overnight at
room temperature to Mayo Clinic, Rochester, MN where
it was processed for immune phenotyping.
Immune-phenotyping peripheral blood from healthy
volunteers and sarcoma patients
Leukocytes were analyzed by direct antibody staining of
whole blood and analyzed by flow cytometry. The protocol
for whole blood staining was adapted from Appay et al.
with full details described in Gustafson et al. [15, 16]. Data
were acquired on a BD FACSCalibur flow cytometer
(Becton Dickinson, Frankin Lakes, NJ) that was cali-
brated on the day of use and analyzed with FlowJo
(Tree Star Inc., Ashland, OR) software. Cell counts
were measured using Trucount™ tubes according to
manufacturer’s directions (BD Biosciences, San Jose,
CA). Data were analyzed with Cell Quest and Multiset
(Becton Dickinson) software. The antibodies against
cell surface markers used for these studies were ob-
tained from BD Biosciences. The specific markers are
listed in Additional file 1. Examples from HV and sar-
coma patients for CD14, HLA-DR, CD4 and CTLA-4
can be found in Additional file 2. Gating strategies and
descriptions of other immune phenotypes have been
described elsewhere [16–20].
Patient tissue samples and immunohistochemistry
Formalin-fixed paraffin embedded archived diagnostic
biopsy samples of the patients enrolled in this study
were retrieved from the PCH tissue bank. Serial 5 μm
sections were obtained for immunohistochemical ana-
lysis. Slides were loaded onto Bond-III auto-stainer,
deparaffinized and retrieved in EDTA for 30 min. Bond
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antibody. Primary CD3 antibody (DAKO #M-7254
Mouse Monoclonal (clone: F7.2.38)) was incubated for
15 min followed by post primary-alkaline phosphatase
(AP) for 30 min, polymer- AP for 30 min and red chro-
magen for 15 min. Slides were rinsed in Bond Wash be-
tween each of the steps. Slides were counterstained with
hematoxylin and taken off the auto-stainer, dehydrated
in graded ethyl alcohol, cleared in xylene and cover
slipped in permanent mounting media. CD14 staining
(Sigma #HPA001887 Rabbit Polyclonal) was as above ex-
cept the EDTA retrieval was for 20 min and brown chro-
magen was used. The slides were reviewed by two
independent pathologists and graded for monocytic
(CD14) and lymphocytic (CD3) infiltration as follows: 1+
(<10 %), 2+ (10-25 %), 3+ (25-50 %) and 4+ (>50 %).
Multiparameter analysis and hierarchical clustering
Hierarchical clustering of immune markers was per-
formed as described by Gustafson et al. [18]. Briefly, cell
counts from 9 immune markers (Granulocytes, lympho-
cytes, monocytes, T cells, B cells, NK cells, CD4+ T cells,
regulatory T cells, and CD14+HLA-DRlo/neg monocytes)
were either measured directly in cells/μl or converted
into cells/μl. An immune marker ratio for each individual
(HV and patients) was determined by dividing the individ-
ual immune marker value by the mean value of the entire
healthy volunteer cohort. The marker ratios for each volun-
teer and patient were imported into Partek Genomics Suite
6.6 software (Partek Inc., St. Louis, MO) and log-
transformed for hierarchical clustering. Hierarchical
clustering was performed by unsupervised agglomera-
tive Euclidean average linkage clustering. Groups were
classified as having ≥5 individuals.
Statistical analysis
All graphical representations and data analysis were per-
formed using Prism 5.0 software (GraphPad, La Jolla,
CA). For the immune phenotyping results, values be-
tween groups of data were tested for statistical signifi-
cance using the Mann Whitney t test for unmatched
groups and the non-parametric Spearman test for corre-
lations. The Fisher’s exact test was used to determine
the significance of the distribution of sarcoma and HV
immune profiles. The significance level was set at prob-
ability of significance set at less than 0.05 with specific
calculated P values provided when applicable. The data




Twenty patients, 11 with OS and 9 with ES were en-
rolled on the study along with 16 HV. One patient withES was ineligible for immmunephenotyping analysis due
to inadequate amount of blood collected for analysis.
Median age of the patients was 14 years (range 6–22
years); and of the HV was 25 years (range 20–30 years).
Patient demographics, diagnosis, and clinical data are
listed in Table 1.
Pediatric sarcoma patients have an altered peripheral
blood leukocyte distribution
In effort to understand the breadth and depth of im-
munological changes in sarcoma patients, we analyzed
the basic white blood cell composition in the peripheral
blood of sarcoma patients (n = 19) and HV (n = 16) using
flow cytometry. Leukocytes from sarcoma patients had a
higher percentage of granulocytes (67 % sarcoma pa-
tients vs. 58 % HV; p = 0.003) and a lower percentage of
lymphocytes (20 % sarcoma patients vs. 27 % HV; p =
0.001). There was no difference in the percentage of
monocytes between the two groups (Fig. 1a). No differ-
ence was seen in the total T-cell, B-cell and NK cell
population between sarcoma patients and HV (Fig. 1b).
However, on analysis of T-lymphocyte subsets the sar-
coma patients had lower CD4 T cells as compared to
HV (697 CD4 cells/ μL vs. 983 CD4 cells/ μL respect-
ively; p = 0.02). No difference was seen in CD8 T cells
between the 2 groups (p = 0.82) leading to an altered
CD4/CD8 ratio in patients (p = 0.04) (Fig. 1c). This dif-
ference in CD4 T cells was primarily seen in ES patients
(596 CD4 cells/ vs. 874 CD4 cells/μL; p = 0.01) (Fig. 1d).
Pediatric sarcoma patients have evidence of immune
modulating phenotypes
In addition to the leukocyte differences observed above,
we identified several other altered phenotypes in sar-
coma patients. Sarcoma patients had increased expres-
sion of CTLA-4, a T-cell inhibitory receptor, on both
CD4 (38 % sarcoma vs. 16 % HV; p = 0.05) and CD8 T
cells (37 % sarcoma vs. 12 % HV; p = 0.05) as compared
to HV (Fig. 1e). In the B-cell compartment, an increase
in class-switched memory B-cells (CD27 + IgM-IgD-)
was seen in sarcoma patients vs. HV (115 vs. 5 % re-
spectively; p = 0.02) (Fig. 1f ). We also analyzed the per-
ipheral blood of OS and ES patients for a previously
described class of immune suppressive monocytes,
CD14+HLA-DRlo/neg monocytes [16, 20–22]. These cells
have been shown in adult glioblastoma, lymphoma,
prostate cancer and CLL to have effects both directly
(with an inability to generate dendritic cells, and inhibit
T cell proliferation) and systemically through expression
of arginase one [16, 20–22]. Increased CD14+HLA-
DRlo/neg immunosuppressive monocytes were seen in
sarcoma patients as compared to HV (15 % vs. 4 % re-
spectively; p = 0.03) (Fig. 1g). This group effect existed
because of the preponderance of these cells in OS
Table 1 Patient characteristics
Patient number Diagnosis Age (years) Gender Primary site Metastases Enrollment Prior therapy From last therapy Blood analysis Tissue analysis (months since)
1 OS 16 Male Distal femur B/L Pulmonary ND None NA Yes Yes Local Relapse 30 months,
alive, NED
2 OS 18 Male Pelvis None ND None NA Yes No DOD
3 OS 12 Female Proximal humerus None ND None NA Yes Yes NED 24 mths
4 OS 10 Female Proximal humerus U/L pulmonary ND None NA Yes Yes Local Relapse 27 months,
alive, NED
5 OS 21 Male Distal femur None ND None NA Yes No NED 27 mths
6 OS 13 Female Proximal tibia None ND None NA Yes Yes Died of pulmonary embolism
during surgery
7 OS 16 Female Distal femur None ND None NA Yes Yes NED 20 mths
8 OS 14 Female Proximal tibia None ND None NA Yes Yes NED 20 mths
9 OS 7 Male Distal femur None ND None NA Yes Yes NED 19 mths
10 OS 15 Male Craniofacial None ND None NA Yes No NED 19 mths
11 OS 12 Female Distal femur B/L Pulmonary ND None NA Yes Yes DOD 22 mths
12 ES 14 Female Scapula None Relapse VDC/ IE 12 weeks Yes Yes DOD 36 mths
13 ES 19 Male Pelvis B/L Pulmonary Relapse VDC/ IE 8 weeks Yes Yes DOD 28 mths
14 ES 18 Male Spine None ND None NA Yes No Died in a car accident 6 mths
after diagnosis
15 ES 13 Male Pelvis None ND None NA Yes Yes NED 29 mths
16 ES 22 Male Chest wall None Relapse VDC/ IE 4 years Yes No NED 72 mths
Diffuse bone and DOD 13
17 ES 6 Female Scapula bone marrow ND None NA No Yes mths
18 ES 13 Female Sacrum None ND None NA Yes Yes NED 20 mths
19 ES 7 Male Mandible proximal None ND None NA Yes No NED 17 mths
20 ES 13 Male Humerus None ND None NA Yes Yes NED 15 mths
DOD- died of disease
NED- no evidence of disease
ND- new diagnosis














Fig. 1 Alterations in peripheral blood immune phenotypes in pediatric sarcoma patients. Immune phenotypes from healthy volunteers and pediatric
sarcoma patients were measured by flow cytometry. a. The percentages of granulocytes, lymphocytes, and monocytes of total leukocytes as measured
by forward and side scatter properties in healthy volunteers and sarcoma patients. Comparison of cell counts (Cells/μl) of: b, T cells (Left axis), B cells
(Right axis), and NK cells (Right axis); c, CD4, CD8 and the CD4:CD8 ratio (CD4 cell counts/CD8 cell counts); d, CD4 cell counts in osteogenic sarcoma
versus Ewing’s sarcoma; e, CTLA-4+ CD4 and CD8 cells. Increases in the percentages of f, CD19+CD27+IgD−IgM− B cells and g, CD14+HLA-DRlo/neg
monocytes; h, and an increase of expression of TNFRII (by mean flourescenc intensity) on monocytes was observed in sarcoma patients. P values are
listed where values are < 0.05
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expression of tumor necrosis factor receptor II was seen
on CD14+ monocytes derived from sarcoma patients as
compared to HV (p = 0.01) (Fig. 1h). Notably, we did not
see any increase in regulatory T cells or LIN−CD33
+HLA-DR− myeloid derived suppressor cells (MDSC) in
peripheral blood of sarcoma patients as compared to
HV. The complete results for all immunophenotypes in
HV and sarcoma patients and associated P values are
listed in Additional file 3.
Hierarchical clustering of immune phenotypes reveals
immunosuppressive profiles in sarcoma patients
The generation of immune profiles from the measure-
ments of multiple immune phenotypes provides a more
complete picture of the immune status of patients. We
have previously shown that patients with profiles otherthan those seen in healthy patients experience a negative
impact on cancer patient survival [18]. We applied this
approach to our sarcoma cohort using nine immune
phenotypes that have been previously shown to cluster
patients in clinically meaningful groups [18]. Clustering
analysis of HV and sarcoma patients revealed two major
groups (Fig. 2a). Group 1 contained 16 HV and 10 sar-
coma patients whereas group 2 had 6 patients with no
HV (p = 0.0177, Fisher’s exact test). 1 HV and 2 sarcoma
patients did not cluster into any group. ES and OS pa-
tients did not differentially subgroup in this analysis.
This result suggests that sarcoma patients in Group 1
have an immune profile similar to healthy volunteers
and that sarcoma patients in Group 2 have an abnormal
immune profile. While no patients in group 1 died due
to disease progression, we found that 3 out of 8 patients
that clustered outside of group 1 died from their disease.
Fig. 2 (See legend on next page.)
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Fig. 2 Hierarchical clustering of immune phenotypes reveals potential differential subgrouping of sarcoma patients based on compositional
changes in peripheral blood immune phenotypes. a. Hierarchical clustering dendrogram showing the relationships of healthy volunteers and
sarcoma patients based on nine immune phenotypes (DRneg- CD14+HLA-DRlo/neg monocytes; M- monocytes; G- granulocytes; NK- natural killer
cells; CD4- CD4 T cells; T- T cells; B- B cells; Treg- CD4+CD25+CD127lo T cells). Profiles were defined by including a minimum of 5 individuals.
Values shaded in red indicate values above the mean of the HV value and blue indicates values below. Two profiles of groups were identified. b.
Hierarchical clustering also can reveal relationships of immune phenotypes to each other. The percentage and cell counts of CD14+HLA-DRlo/neg
monocytes correlated to the cell counts of monocytes and the cell counts of CD14+HLA-DRlo/neg monocytes correlated to the cell counts of
granulocytes. c. Illustrative comparisons of the compositional differences in healthy volunteers and sarcoma patients. For total white blood cells
(WBCs); the percentages of granulocytes (gray), lymphocytes (purple), and monocytes (orange) are shown. The pie graphs are also sized based on
cell counts where the sarcoma pie graph is sized in proportion to the HV pie graph. Mononuclear cells (MNCs) show CD4 T cells (dark blue),
Tregs (white), CD8 T cells (light blue), B cells (green), NK cells (yellow), CD14+HLA-DR+ monocytes (black), and CD14+HLA-DRlo/neg monocytes
(red). The sarcoma pie graph is sized in proportion to the HV graph
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ger cohort of adult cancer patients where the abnormal im-
mune profiles adversely affected survival [18]. One of the
distinguishing immunophenotypes between sarcoma pa-
tients in group 1 versus 2 was the levels of CD14+HLA-
DRlo/neg monocytes. Sarcoma patients in profile 1 had
CD14+HLA-DRlo/neg monocytes similar to the levels in
healthy volunteers in terms of cell counts and percentages
(mean: 39.9 cells/μl and 9.2 ± 9.6 % of CD14+ monocytes)
whereas sarcoma patients in group 2 had significantly ele-
vated CD14+HLA-DRlo/neg monocytes (307.7 cells/μl (p =
0.0087 vs. profile 1 and 30.2 ± 15.9 % (p = 0.011)). Hierarch-
ical clustering can also reveal novel relationships between
immune phenotypes. Granulocytes, monocytes, and CD14
+HLA-DRlo/neg monocytes clustered together suggesting
that changes in these populations are related. Indeed, the
levels of CD14+HLA-DRlo/neg monocytes from all sarcoma
patients, in both cell counts (cells/μl) and percentage of
total CD14+ monocytes, were positively correlated to the
monocyte cell counts (Fig. 2b). In addition, CD14+HLA-
DRlo/neg monocyte cell counts correlated to the granulocyte
counts. Finally, we can quantify the entire leukocyte popu-
lation of sarcoma patients by representing the immune
profiles as a pie chart. Figure 2c shows pie charts that rep-
resent an immune profile from healthy volunteers and sar-
coma patients in both terms of total leukocytes (WBCs)
and mononuclear cells (MNCs). The size of the pie chart is
relative to the healthy volunteer profile. The total leukocyte
population of sarcoma patients is approximately 50 % larger
than the healthy volunteer profile whereas the mononuclear
compartment is very similar. Although the total size of the
sarcoma MNC compartment is similar to healthy volun-
teers, the distribution of subsets is quite different. Taken to-
gether, these data identify an immune profile in sarcoma
patients characterized by increased CD14+HLA-DRlo/neg
monocytes, total monocytes, and granulocytes.
Significant infiltration of CD14+ cells is present in
osteosarcoma primary tumors
We have previously shown that for glioblastoma and
renal cell carcinoma patients, an increase in peripheralblood CD14+HLA-DRlo/neg monocytes was associated
with increased infiltration of CD14+ cells within the
tumor [16, 23]. We analyzed the diagnostic biopsy sam-
ples of patients enrolled on this study for lymphocytic
and CD14+ infiltration by immunohistochemistry. Eight
OS patient samples and six ES samples were available
for analysis. CD3 cell surface marker was used for
lymphocyte identification in addition to CD14 identifica-
tion in tumor tissues. Minimal tumor-associated T cell
infiltration was seen in both OS and ES tumors (<10 %
in 12/14 tumors and 10-25 % in 2/14 tumors). In con-
trast, OS specimens had marked CD14+ infiltration in
the majority of the tissues (>50 % in 7/8; 10-25 % in 1/8
tumors) (Fig. 3).
Discussion
Evidence of immune dysregulation is found in several
human cancers and is believed to be an important es-
cape mechanism for the tumor cells from the host im-
mune system. Limited data exists in pediatric bone
sarcomas regarding the underlying immune deficits. In
the current study, we performed detailed immune phe-
notyping analysis in patients with OS and ES to better
characterize the immune system of these patients.
Our data demonstrates that pediatric sarcoma patients
exhibit alterations in the distribution leukocytes whereby
granulocyte cell counts are elevated in peripheral blood
thus reducing the overall percentage of lymphocytes and
CD4 lymphopenia that is more profound in ES patients.
We acknowledge that the healthy volunteer cohort was
older than the pediatric sarcoma cohort; however, there
are several reports in the pediatric literature that suggest
that the frequencies and cell counts between the ages of
6–24 do not substantially change [24–26]. Reference
values for many of the phenotypes we measured here
have not been established or reported. Therefore, our
data provides a framework for future studies in pediatric
sarcoma. Lymphopenia at diagnosis in adults is consid-
ered to be a poor prognostic factor in soft tissue sar-
coma [27]. In both OS and ES, early lymphocyte
recovery after chemotherapy courses has been shown to
Fig. 3 CD14+ monocytes accumulate in sarcoma tumors. Immunohistochemical analysis was performed using CD14 antibody for monocytic
infiltration and CD3 antibody for lymphocytic infiltration on primary tumor tissues of OS and ES patients; a, b, c represent CD14 staining (brown)
in tonsil control, ES and OS respectively; d, e, f represent CD3 staining (red) in tonsil control, ES and OS respectively
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[28, 29]. In preclinical studies, immune reconstitution pre-
vented the development of metastasis in a murine model
of OS [30]. Our data goes beyond the description of ab-
normal leukocyte distributions; that is, we have identified
specific alterations in immune populations that have pre-
viously been implicated in immune suppression in a var-
iety of cancers, including B-cell non-Hodgkin lymphoma,
prostate, CLL and GBM [16, 20–22].
Differences in immune markers were observed both in
peripheral blood and in tumor tissues of OS and ES pa-
tients. ES patients demonstrated a lower absolute CD4 T
cell count as compared to HV but no such difference
was observed in OS. We did not observe a difference in
the absolute Treg count in peripheral blood of ES pa-
tients, which is contrary to the data published before
showing higher Tregs in the bone marrow of ES patients
with metastatic disease. Increased expression of the in-
hibitory T cell receptor CTLA-4 on CD4 and CD8 T
cells in sarcoma patients may have direct implications
for immune therapy. CTLA-4 expression was noted in
OS cell lines and patient tumor samples [31] and
CTLA-4 + 49G/A polymorphism was associated with in-
creased risk of developing OS [32]. Combined treatment
with anti-CTLA-4 antibody and tumor lysate-pulsed
dendritic cells in mice with OS lead to decreased Tregs
and increased CD8 T cells in metastatic tumor leading
to decreased metastasis and increased EFS [33]. Taken
together, CTL-4 targeted therapy may be beneficial, andit will be important to evaluate the effect of this therapy
based on the expression on T cells or tumor tissue. Not
all of our data can be interpreted in the context of im-
mune suppression. For example, CD69 (typically a
marker of T cell activation) was seen on CD4+ T cells.
Additional markers of T cell anergy and/or exhaustion
(i.e. PD-1 and TIM-3) and functional data may help clar-
ify the impact of these alterations in sarcoma patients.
Increased numbers of CD14+HLA-DRlo/neg monocytes
in the peripheral blood of OS patients has previously been
shown to be immunosuppressive in a variety of cancers
such as prostate cancer, non-Hodgkin lymphoma (NHL),
glioblastoma multiforme, and chronic lymphocytic
leukemia [16, 20–22]. CD14+HLA-DRlo/neg monocytes
suppress autologous T cell proliferation and are defective
in their ability to differentiate into mature dendritic cells
in cancer patients [34]. In patients with NHL, elevated
levels of CD14+HLA-DRlo/neg monocytes were associated
with more aggressive disease and suppressed immune
functions via multiple mechanisms including altering
STAT signaling, increasing IDO, arginase, iNOS, NOX2
and VEGF expression, preventing DC maturation, altering
co-stimulatory and cytokine expression and decreasing
antigen uptake as summarized in a recent review by
Laborde et al. [34]. In addition, others have shown that
CD14+HLA-DRlo/neg monocytes suppress T cell function
and proliferation by secreting arginase I, IDO, and TGF-
beta [35–37]. As the interaction between tumor cells and
monocytes appears to promote the loss of HLA-DR on
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cytes would likely be present in the tumor microenviron-
ment. In primary tumor tissues, both OS and ES tissues
had limited tumor-infiltrating lymphocytes but 87 % of OS
tissues (n = 8) had a significant (>50 %) CD14+ cell infil-
tration while 83 % of ES tissues (n = 6) had less than 25 %
CD14+ cell infiltration. We believe that the association of
greater tumor infiltration of CD14+ cells and greater num-
bers of CD14+HLA-DRneg cells with advanced disease
strongly suggests that these cells may be part of the patho-
genesis of these tumors and should be further investigated
as high priority targets for new therapies.Conclusions
This study was designed to establish a global overview of
immune status in this rare patient cohort and to identify
immune phenotypes that are relevant to the pathology
of pediatric sarcomas. We have identified several im-
mune phenotypes that are altered in pediatric sarcomas
including elevated CD14+ HLA-DRlo/neg cells, elevated
CTLA-4+ T cells, and decreased CD4 T cells. This initial
exploration of immune phenotypes will likely need to be
validated in a larger cohort with fewer, more targeted
phenotypes. Additionally, future studies should be
followed by functional studies to further develop im-
munotherapy treatment protocols focusing on correcting
specific immune deficiencies. Specific targets of im-
munotherapy in OS and ES will likely include reconsti-
tution of the CD4 T cell pool, removing inherent
immune suppression (such as reversing the CTLA-4
phenotypes), reducing granulocytes and eliminating
CD14+ HLA-DRlo/neg cells. Recent trials applying im-
mune inhibitory pathway inhibitors such as anti-CTLA-
4 [38] and anti-PD-1 [39] agents in metastatic melanoma
demonstrated a significantly improved progression free
survival in patients and are a testament to the import-
ance of immune inhibitory pathways in cancer patho-
genesis. It is our belief that similar therapeutic strategies
may be effective in pediatric sarcomas. These studies in
combination with extensive immune characterization
may lead to improvements in matching appropriate ther-
apies to patients, improving appropriate treatment time
and identifying the correct immune modulating therapy
combinations for patients.Additional files
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